Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Nyxoah (NASDAQ: NYXH) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 15, 2026. The presentation begins at 12:00 PM PT. A live audio webcast will be available on the company's investor relations website at investors.nyxoah.com.
This presentation offers investors a chance to hear management's update on Nyxoah's neuromodulation therapy for obstructive sleep apnea and company strategy directly from executives.
Positive
- None.
Negative
- None.
News Market Reaction – NYXH
In the Dec 30 session, NYXH declined 2.11%, reflecting a moderate negative market reaction. Argus tracked a peak move of +3.3% during that session. Argus tracked a trough of -60.4% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. Trading volume was very high at 3.3x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 19 | Convertible bond financing | Negative | -2.1% | First tranche of €22.5M convertible bonds with 6.5% coupon and 3-year term. |
| Dec 17 | Product launch | Positive | +0.0% | Commercial launch of Genio bilateral neurostimulation system in the Netherlands. |
| Dec 02 | Ownership disclosure | Neutral | -0.7% | Transparency notifications on voting-rights changes for a major shareholder. |
| Nov 27 | Conference participation | Neutral | +2.8% | Participation in Piper Sandler healthcare conference with webcasted fireside chat. |
| Nov 20 | Capital structure update | Neutral | +1.5% | Publication of updated share capital, voting rights, and subscription rights figures. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has often seen muted or contrary price reactions, with only the November conference participation aligning clearly with a positive move.
Over the last six weeks, Nyxoah combined financing, corporate disclosures and commercial progress. A November 17 prospectus and subsequent multi-part financings, including convertible notes, expanded funding for Genio commercialization. November disclosures on total voting rights and later transparency notifications updated ownership and capital structure. Nyxoah also highlighted investor-relations activity via the Piper Sandler conference and announced the commercial launch of the Genio system in the Netherlands. Today’s J.P. Morgan conference appearance continues this pattern of investor-facing communication rather than a new clinical or regulatory milestone.
Key Terms
obstructive sleep apnea medical
neuromodulation medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference
Mont-Saint-Guibert, Belgium – December 29, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, Jan. 15, 2026. The Company's presentation will begin at 12:00 pm PT.
A live audio webcast of the presentation will be available online on the investor relations page of the Company’s website at investors.nyxoah.com.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.
Contact:
Nyxoah
John Landry, CFO
IR@nyxoah.com
Rémi Renard
Chief Investor Relations & Corporate Communication Officer
IR@nyxoah.com
Attachment
